ArticleCurrent opinion in chemical engineering2015
Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery.
Article in Current opinion in chemical engineering, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Peptide Coacervates Promote Cytosolic Delivery of STING Agonists for Cancer Immunotherapy.Vaccines · 2026Article
- ICAM-1 identifies preadipocytes and restricts white adipogenesis by adhering immune cells.Cell death and differentiation · 2026Article
- Concerns and challenges in clinics-guided nanovaccines design and applications.Acta pharmaceutica Sinica. B · 2026Review
- Treatment strategies for rituximab-resistant primary membranous nephropathy: from resistance mechanisms to emerging therapies.Frontiers in immunology · 2026Review
- Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity.ACS applied materials & interfaces · 2025Article
- Engineering Lymphatic Transport of Nanoparticles through Emulsion Polymerization.ACS applied materials & interfaces · 2025Article
- Article
- Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) againstBioactive materials · 2025Article
- Emerging strategies in lymph node-targeted nano-delivery systems for tumor immunotherapy.Essays in biochemistry · 2025Review
- Nanomaterial Adjuvants for Veterinary Vaccines: Mechanisms and Applications.Research (Washington, D.C.) · 2025Review
- Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring.Nano convergence · 2024Review
- Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.Science advances · 2024Article
- A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.ACS nano · 2024Article
- Hyaluronic acid modified indocyanine green nanoparticles: a novel targeted strategy for NIR-II fluorescence lymphatic imaging.Frontiers in chemistry · 2024Article
- Broad and Durable Humoral Responses Following Single Hydrogel Immunization of SARS-CoV-2 Subunit Vaccine.Advanced healthcare materials · 2023Article
- Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives.Journal of nanobiotechnology · 2023Review
- Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.Journal of nanobiotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite drug formulation improving circulation times and targeting, efficacy is stymied by inadequate penetration into and retention within target tissues. This review highlights the barriers restricting delivery to the connective tissue interstitium, lymphatics, and lymph nodes as well as advances in engineering drug carriers to overcome these delivery challenges. Three-dimensional tissue physiology is discussed in the context of providing material design principles for delivery to these tissues; in particular the influence of interstitial and lymphatic flows as well as differential permeabilities of the blood and lymphatic capillaries. Key examples of materials with different characteristics developed to overcome these transport barriers are discussed as well as potential areas for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.